CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.63) by 40.13 percent. This is a 10 percent decrease over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $8.726 million which beat the analyst consensus estimate of $966.667 thousand by 802.69 percent. This is a 303.61 percent increase over sales of $2.162 million the same period last year.